(DNLI) Denali Therapeutics - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 3.071m USD | Total Return: 38.4% in 12m
Avg Turnover: 36.3M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Altman Z'' -0.87 < 1.0 - financial distress zone
Fakeout Choppy
Tailwinds
No distinct edge detected
Denali Therapeutics Inc. is a South San Francisco-based biopharmaceutical firm specializing in therapies for neurodegenerative and lysosomal storage diseases. Its research focuses on crossing the blood-brain barrier using its proprietary Transport Vehicle (TV) technology platform to deliver enzymes and antibodies to the central nervous system. The company’s pipeline includes candidates for high-prevalence conditions such as Alzheimer’s and Parkinson’s disease, alongside treatments for rare genetic disorders like Hunter Syndrome and Sanfilippo Syndrome.
The biotechnology sector often utilizes a partnership-heavy business model to mitigate high R&D costs; Denali maintains strategic collaborations with industry leaders such as Sanofi, Biogen, and Takeda. Success in this sector is heavily contingent on clinical trial outcomes and regulatory approval phases, which dictate the long-term commercial viability of developmental assets. For a deeper analysis of these clinical stages and their impact on valuation, consider reviewing the data on ValueRay.
- Clinical trial results for Hunter Syndrome lead asset DNL310 drive near-term valuation
- Strategic partnerships with Biogen and Takeda provide essential non-dilutive R&D funding
- Success of proprietary Blood-Brain Barrier Transport Vehicle technology validates entire platform pipeline
- Regulatory milestones for LRRK2 inhibitor program impact long-term Parkinson’s disease market outlook
- High cash burn rate necessitates continued clinical progress to avoid dilutive financing
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA -3.50 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.33 > 3% & CFO -412.3m > Net Income -508.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (186.6m) vs 12m ago 9.00% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.72 (Total Current Assets 1.02b - Total Current Liabilities 110.2m) / Total Assets 1.27b |
| B: -1.72 (Retained Earnings -2.18b / Total Assets 1.27b) |
| C: -0.42 (EBIT TTM -538.2m / Avg Total Assets 1.27b) |
| D: 2.72 (Book Value of Equity 926.1m / Total Liabilities 339.9m) |
| Altman-Z'' = -0.87 = CCC |
As of June 12, 2026, the stock is trading at USD 21.02 with a total of 1,918,924 shares traded.
Over the past week, the price has changed by +4.37%,
over one month by +6.86%,
over three months by -2.73% and
over the past year by +38.38%.
Denali Therapeutics has received a consensus analysts rating of 4.79. Therefore, it is recommended to buy DNLI.
- StrongBuy: 15
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 33.9 | 61.4% |
P/S = 3643.6484
P/B = 3.4995
Revenue TTM = 0.0 USD
EBIT TTM = -538.2m USD
EBITDA TTM = -523.8m USD
Long Term Debt = 30.2m USD (estimated: total debt 40.0m - short term 9.86m)
Short Term Debt = 9.86m USD (from shortTermDebt, last quarter)
Debt = 74.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 34.5m
Net Debt = -891.6m USD (calculated: Debt 74.6m - CCE 966.1m)
Enterprise Value = 2.18b USD (3.07b + Debt 74.6m - CCE 966.1m)
Interest Coverage Ratio = unknown (Ebit TTM -538.2m / Interest Expense TTM 0.0)
EV/FCF = -5.36x (Enterprise Value 2.18b / FCF TTM -406.6m)
FCF Yield = -18.65% (FCF TTM -406.6m / Enterprise Value 2.18b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 110.7m) / Revenue TTM)
Tobins Q-Ratio = 1.72 (Enterprise Value 2.18b / Total Assets 1.27b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 74.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -425.2m (EBIT -538.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.79 (Total Current Assets 1.02b / Total Current Liabilities 150.5m)
Debt / Equity = 0.08 (Debt 74.6m / totalStockholderEquity, last quarter 926.1m)
Debt / EBITDA = 1.70 (negative EBITDA) (Net Debt -891.6m / EBITDA -523.8m)
Debt / FCF = 2.19 (negative FCF - burning cash) (Net Debt -891.6m / FCF TTM -406.6m)
Total Stockholder Equity = 973.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.04% (Net Income -508.0m / Total Assets 1.27b)
RoE = -52.20% (Net Income TTM -508.0m / Total Stockholder Equity 973.3m)
RoCE = -53.63% (EBIT -538.2m / Capital Employed (Equity 973.3m + L.T.Debt 30.2m))
RoIC = -36.47% (negative operating profit) (NOPAT -425.2m / Invested Capital 1.17b)
WACC = 11.14% (E(3.07b)/V(3.15b) * Re(11.41%) + D(74.6m)/V(3.15b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 14.27%
[DCF] Fair Price = unknown (Cash Flow -406.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.21 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.41 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.53 | Chg30d=-39.97% | Revisions=+27% | Analysts=14
EPS next Quarter (2026-09-30): EPS=-0.53 | Chg30d=+19.74% | Revisions=+33% | Analysts=14
EPS current Year (2026-12-31): EPS=-2.32 | Chg30d=+9.02% | Revisions=+50% | GrowthEPS=+21.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.48 | Chg30d=+4.07% | Revisions=+71% | GrowthEPS=-6.8% | GrowthRev=+176.0%
[Analyst] Revisions Ratio: +71%